All In Biotech

Drug Trial Radar · NCT06152042

Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

Phase 2 Randomized, Double-blind Trial of BMF-219 Compared to Placebo in Participants With Type 1 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Dec 28, 2023

Primary completion

May 20, 2025

Study completion Jul 18, 2025

Sponsor

Lead sponsor
Biomea Fusion Inc.Industry
Sponsor type
Industry
First posted
Nov 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • BMF-219Drug

    BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the effect on endogenous insulin secretionTime frame: 26 Weeks

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Oceanic Research Group

    North Miami Beach, Florida

  • Lucas Research, Inc.

    Morehead City, North Carolina

  • Alliance for Multispecialty Research, LLC.

    Norman, Oklahoma

  • University Diabetes & Endocrine Consultants

    Chattanooga, Tennessee

  • Velocity Clinical Research

    Dallas, Texas

  • Texas Diabetes & Endocrinology

    Round Rock, Texas

  • Diabetes & Glandular Disease Clinic, P.A.

    San Antonio, Texas

  • Consano Clinical Research, LLC

    Shavano Park, Texas

  • Manassas Clinical Research Center

    Manassas, Virginia

  • Dr. T.G Elliott Inc. dba BC Diabetes

    Vancouver, British Columbia, Canada

  • Centricity Research

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.